Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

DISEASE CHARACTERISTICS: Inclusion criteria: * Diagnosis of hepatic neuroendocrine metastases not suitable for radical therapies (e.g., resection or liver transplantation) * Histologically proven neuroendocrine tumor * Tumors are hypervascular based on visual estimation by investigator * Predominant to the liver disease, but extrahepatic disease is not an exclusion * No predominant extrahepatic liver disease * No significant life-threatening extrahepatic disease, in the judgment of the physician * Recent-interval progression of hepatic liver metastases * No diffuse hepatic neuroendocrine metastases defined as massive ill-defined tumor involvement measuring \> 90% tumor burden Exclusion criteria: * Clinically evident ascites (a radiographic finding of trace ascites on imaging is acceptable) * Complete occlusion of the entire portal venous system * Evidence of cirrhosis or portal hypertension * Vascular resistance peripheral to the feeding arteries precluding passage of PVA microporous hydrospheres/doxorubicin hydrochloride PATIENT CHARACTERISTICS: Inclusion criteria: * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Must have preserved liver function (Child-Pugh class A-B) without significant liver decompensation * No advanced liver disease (e.g., Child-Pugh C class or active gastrointestinal bleeding, encephalopathy, or ascites \[trace ascites is acceptable\]), meeting the following criteria: * Bilirubin \> 3 mg/dL * Aspartate a…